DBV Technologies appoints Professor Robert Zeiger to its Scientific Advisory Board

DBV Technologies increases expertise in peanut allergy diagnosis and treatment

Paris, France – 18 December 2009 – DBV Technologies (DBV), a biopharmaceutical company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies (EPIT) for allergies, announces the appointment of US-based food allergy and paediatric asthma specialist Professor Robert Zeiger to its Scientific Advisory Board.

In joining the Scientific Advisory Board, Professor Zeiger will provide DBV Technologies with access to his expertise in food allergy diagnosis and prevention as well as paediatric asthma diagnosis and treatment. Professor Zeiger’s appointment is of strategic importance to DBV Technologies, as the Company works towards the initiation of its first US Phase I clinical trial for peanut allergy.

Professor Zeiger, a MD, PhD, is a Clinical Professor in the Department of Paediatrics at the UCSD School of Medicine in La Jolla, California, United States and Adjunct Physician Investigator for Kaiser Permanente Southern California. Professor Zeiger’s current research activities focus on determining whether high-dose Vitamin D supplementation during pregnancy prevents asthma and allergies in infants, clinical trials in paediatric asthma to determine optimal asthma treatments, and unravelling the effect of childhood asthma on adult lung health. In addition, Professor Zeiger serves on the Medical Advisory Boards for the Food Allergy and Anaphylaxis Network (FAAN) and the Food Allergy Initiative (FAI), lay organizations whose role is to promote food allergy education and provide support for food allergy research.

Commenting on the appointment, DBV Technologies Chairman and CEO Jean-François Biry said, “We are delighted to have Professors Zeiger’s support behind our VIASKIN® technology and our EPIT peanut allergy desensitization programme. Professor Zeiger’s experience in food allergy, clinical trial design and performance, infant lung function, asthma diagnosis and treatment will help DBV to accelerate our clinical development”. Professor Zeiger’s enthusiasm in joining the Scientific Advisory Board is noted in his comment that “the epidemic increase in food allergy seen throughout most of the world must be challenged with new and innovative diagnostic techniques and therapies. DBV’s non-invasive epicutaneous diagnostics and immunotherapies (EPIT) provide the potential instruments to alter this epidemic”.